New versatile genetic testing for lymphoid tumors supports individualized patient management

Credit: Unsplash / CC0 public domain

Increased knowledge of genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignancies. LYmphoid NeXt-Generation Sequencing (LYNX), a new integrated capture-based next-generation sequencing (NGS) panel, can simultaneously detect and analyze the most common lymphoid tumor standards and novel biomarkers. This represents an important step towards more effective personalized treatment of these diseases and facilitates further research. Molecular diagnostic journal..

Genome profiling by NGS provides new and important clinical information on prognostic and predictive biomarkers. NGS studies have identified several genomic alterations in hematopoietic malignancies, providing a better understanding of the evolution of these neoplasms as well as the course of the disease.

Dr. Sarka Pospisilova, Principal Researcher at Masaryk University School of Medicine and University Hospital, said: Brno; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. “Therefore, we wanted to design, validate, and implement a new custom-designed NGS panel for integrated analysis of diagnostic, prognostic, and predictive markers.”

Researchers have compiled a list of key genomic biomarkers. Chronic lymphocytic leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular lymphoma (FL), and mantle cell lymphoma (MCL) from publicly available resources, with routine clinical practice Biomedical research..

New versatile genetic testing of lymphoid tumors supports individualized patient management and further research

Integrated into the lymphocytic NeXt production sequencing (LYNX) panel design of the most common lymphocytic malignancies (1 chronic lymphocytic leukemia, 2 mantle cell lymphoma, 3 follicular lymphoma, 4 diffuse large B cells) Schematic diagram of genomic targets and molecular markers Lymphoma, 5 acute lymphoblastic leukemias, and 6 Philadelphia chromosome-like acute lymphoblastic leukemias). cnLOH, heterozygous copy neutral loss; CNV, copy number polymorphism; SNP, single nucleotide polymorphism. credit: Molecular diagnostic journal

“This all-in-one test, which covers a wide range of key biomarkers of lymphoproliferative disorders, is a unique tool for obtaining relevant information about a patient-specific genetic background from a single biological sample,” said the lead author. Dr. Veronika Navrkalova said. .. , From Masaryk University School of Medicine and Brno University Hospital. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

To ensure the accuracy of the test, researchers have verified the reliability of the analytical procedure. This allowed us to fairly identify different prognostic and predictive markers in a single test. In total, 84 DNA samples from 65 patients (30 for CLL, 13 for ALL, 9 for DLBCL, 6 for MCL, 7 for FL) were sequenced in two validation rounds. rice field. The validation sample cohort was carefully selected to obtain representative sets of various mutation types, copy number polymorphisms, common lymphoma translocations, and immunoglobulin / T cell receptor rearrangements.

A single LYNX test sensitively and accurately detects mutations in 70 lymphoma-related genes, reliably identifies genome-wide and recurrent chromosomal abnormalities, and assesses rearrangement of immunoglobulin and T-cell receptor genes And detect lymphoma-specific translocations.

“This represents an important step towards effective management of patients with hematological malignancies,” commented Dr. Pospisilova. “Because this assay is simple and can be used in research, researchers, clinical hematopathologists, and hematopathologists work closely together to demonstrate its clinical utility and benefits to patients with lymphoid malignancies. Needs further prospective testing for. “

The research team believes that the LYNX panel is suitable for routine testing with research and clinical applicability and may support individualized management of patients with lymphoid malignancies. It integrates clinically relevant genomic abnormalities and markers into a single test, monitors disease clonal evolution, and reveals different genetic structures for different lymphoproliferative disorders. In addition, the results obtained from this test can lead to clinical assessment of patient diagnosis, prognosis, and treatment choices, leading to exposure to patient-specific markers that are important for monitoring minimal residual disease. There is a possibility.

Leveraging the power of genomic sequencing enhances the diagnosis and treatment of lymphoid cancers

For more information:
Veronika Navrkalova et al, LYmphoid NeXt-Generation Sequencing (LYNX) Panel, Molecular diagnostic journal (2021). DOI: 10.1016 / j.jmoldx.2021.05.007

Quote: A new versatile genetic test for lymphoid tumors in patients obtained on July 29, 2021 from https: // Supports individual management (July 29, 2021)

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

New versatile genetic testing for lymphoid tumors supports individualized patient management

Source link New versatile genetic testing for lymphoid tumors supports individualized patient management

Related Articles

Back to top button